Journal
DISEASES OF THE COLON & RECTUM
Volume 50, Issue 3, Pages 376-388Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1007/s10350-006-0763-3
Keywords
irritable bowel syndrome; constipation; enterochromaffin cells; 5-HT3 and 5-HT4 receptors
Categories
Funding
- NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062267] Funding Source: NIH RePORTER
- NCRR NIH HHS [P20 RR16435] Funding Source: Medline
- NIDDK NIH HHS [DK62267] Funding Source: Medline
Ask authors/readers for more resources
Serotonin (5-HT) is most commonly thought of as a neurotransmitter in the central nervous system. However, the predominant site of serotonin synthesis, storage, and release is the enterochromaffin cells of the intestinal mucosa. Within the intestinal mucosa, serotonin released from enterochromaffin cells activates neural reflexes associated with intestinal secretion, motility, and sensation. Two important receptors for serotonin that are located in the neural circuitry of the intestines are the 5-HT3 and 5-HT4 receptors, these are the targets of drugs designed to treat gastrointestinal disorders. 5-HT3 receptor antagonists are used to treat nausea and emesis associated with chemotherapy and for functional disorders associated with diarrhea. 5-HT4 receptor agonists are used as promotility agents to promote gastric emptying and to alleviate constipation. Because of the importance of serotonin in normal gut function and sensation, a number of studies have investigated potential changes in mucosal serotonin signaling in pathologic conditions. Despite the inconsistencies in the current literature, changes in serotonin signaling have now been demonstrated in inflammatory bowel disease, irritable bowel syndrome, postinfectious irritable bowel syndrome, and idiopathic constipation. Emerging evidence has led to many contradictory theories regarding serotonin signaling and its roles in the pathology of gut disorders. This review summarizes the current medications affecting serotonin signaling and provides an overview of our current knowledge of the changes in serotonin that occur in pathologic conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available